We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases.
Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US.
We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases
Company Details
- Employees
- 7
- Founded
- -
- Address
- Philips Van Leydenlaan 15, Nijmegen,po Box 9101,6525 Ex,netherlands
- Phone
- +31 24 361 75 05
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- khondrion.com
- Keywords
- Life cell quantitative imaging, inborn errors of energy metabolism, compound development and testing, mitochondrial medicine, rare disease, orphan disease, mitochondrial disease, melas, midd, leigh syndrome, mitochondria.
- HQ
- Nijmegen
Khondrion Questions
Khondrion's helpline number is +31 24 361 75 05
Khondrion's website is khondrion.com
Khondrion's LinkedIn profile is https://nl.linkedin.com/company/khondrion
Khondrion has
7 employees.
View email and phone details for 7
employees at Khondrion.
Khondrion's industry is
Pharmaceutical Manufacturing
Khondrion's top competitors are
Grants.support B.v.,
Rival Foods,
Lemba Therapeutics,
Protinhi Therapeutics,
Vsparticle,
Byondis,
Synthon,
Vaxxinova,
Avivia,
Xenikos B.v..
Khondrion's categories are Pharmaceutical Manufacturing
Khondrion's founding year is 2012
